• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Big biopharma would rather ‘make than buy’

Report: Big biopharma would rather ‘make than buy’

November 12, 2014
CenterWatch Staff

Global and generic biopharma companies will continue to prefer in-house manufacturing to outsourcing for the most strategic elements of their businesses, according to a report by PharmSource Information Services, a Virginia-based provider of market intelligence for the global contract biopharma industry.

Jim Miller, the founder and president of PharmSource and the report’s lead author, said based on detailed research and analysis of the financial investments biopharma companies are making in their captive manufacturing capacity, it’s clear companies would rather “make than buy.”

“Capital expenditure trends are an indicator of the industry’s propensity to outsource its manufacturing requirements,” Miller said. “Our analysis of recent spending indicates that global and generic biopharma companies are not likely to embrace contract manufacturing to any greater degree than they have in the past 10 years.”

In developing the report, Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing, PharmSource researched financial data for nearly 250 publicly traded companies, along with a data set of 84 announced manufacturing and R&D infrastructure investment projects. Miller said the data captures the bulk of industry capital spending and paints a representative picture of how companies are investing in facilities and equipment.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing